IQVIA Holdings Beheer

Beheer criteriumcontroles 3/4

De CEO IQVIA Holdings is Ari Bousbib, benoemd in Oct2016, heeft een ambtstermijn van 8.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 29.15M, bestaande uit 6.2% salaris en 93.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.73% van de aandelen van het bedrijf, ter waarde R$ 1.60B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 8.1 jaar.

Belangrijke informatie

Ari Bousbib

Algemeen directeur

US$29.2m

Totale compensatie

Percentage CEO-salaris	6.2%
Dienstverband CEO	8.1yrs
Eigendom CEO	0.7%
Management gemiddelde ambtstermijn	5.8yrs
Gemiddelde ambtstermijn bestuur	8.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Ari Bousbib's beloning veranderd ten opzichte van IQVIA Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$1b
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$29m	US$2m	US$1b
Sep 30 2023	n/a	n/a	US$1b
Jun 30 2023	n/a	n/a	US$1b
Mar 31 2023	n/a	n/a	US$1b
Dec 31 2022	US$30m	US$2m	US$1b
Sep 30 2022	n/a	n/a	US$1b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	n/a	n/a	US$1b
Dec 31 2021	US$29m	US$2m	US$966m
Sep 30 2021	n/a	n/a	US$767m
Jun 30 2021	n/a	n/a	US$607m
Mar 31 2021	n/a	n/a	US$409m
Dec 31 2020	US$26m	US$2m	US$279m
Sep 30 2020	n/a	n/a	US$176m
Jun 30 2020	n/a	n/a	US$132m
Mar 31 2020	n/a	n/a	US$215m
Dec 31 2019	US$22m	US$2m	US$191m
Sep 30 2019	n/a	n/a	US$244m
Jun 30 2019	n/a	n/a	US$247m
Mar 31 2019	n/a	n/a	US$248m
Dec 31 2018	US$16m	US$2m	US$259m
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$38m	US$2m	US$1b

Compensatie versus markt: De totale vergoeding ($USD 29.15M ) Ari } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de BR markt ($USD 5.73M ).

Compensatie versus inkomsten: De vergoeding van Ari is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ari Bousbib (63 yo)

8.1yrs

Tenure

US$29,151,752

Compensatie

Mr. Ari Bousbib serves as Chairman and Chief Executive Officer at IQVIA Holdings Inc. since October 03, 2016 and also served as its President. He is Director of IQVIA Holdings Inc since October 03, 2016. H...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ari Bousbib	CEO & Chairman	8.1yrs	US$29.15m	0.73% R$ 1.6b
Ronald Bruehlman	Executive VP & CFO	4.3yrs	US$8.56m	0.023% R$ 50.1m
Eric Sherbet	Executive VP	6.7yrs	US$3.97m	0.010% R$ 22.8m
W. Staub	President of Research & Development Solutions	1.2yrs	US$1.93m	0.0085% R$ 18.7m
Keriann Cherofsky	Senior VP	2.3yrs	geen gegevens	0.00034% R$ 747.7k
Jim Berkshire	Executive Vice President of Global Technology & Operations	less than a year	geen gegevens	geen gegevens
Jeffrey Spaeder	Senior VP	no data	geen gegevens	geen gegevens
Kerri Joseph	SVP of Investment Relation & Treasury	less than a year	geen gegevens	geen gegevens
Trudy Stein	Chief Human Resources Officer & Executive VP	8.1yrs	geen gegevens	geen gegevens
Cynthia Verst	President of Design & Delivery Innovation	13.4yrs	geen gegevens	geen gegevens
Andrea Spannheimer	Global Head of Real-World & Late Phase Research	9.1yrs	geen gegevens	geen gegevens
Jon Resnick	President of United States & Canada	5.8yrs	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van I1QV34 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ari Bousbib	CEO & Chairman	8.1yrs	US$29.15m	0.73% R$ 1.6b
John Danhakl	Independent Director	8.1yrs	US$319.93k	0.015% R$ 33.2m
John Connaughton	Independent Director	16.8yrs	geen gegevens	0.00058% R$ 1.3m
John Leonard	Independent Lead Director	9.8yrs	US$367.43k	0.0076% R$ 16.7m
Leslie Morris	Independent Director	2.8yrs	US$309.93k	0.0011% R$ 2.5m
Colleen Goggins	Independent Director	7.3yrs	US$339.93k	0.0062% R$ 13.7m
Todd Sisitsky	Independent Director	8.1yrs	geen gegevens	geen gegevens
Sheila Stamps	Independent Director	2.8yrs	US$314.93k	0.0011% R$ 2.5m
James Fasano	Independent Director	8.1yrs	US$304.93k	0.00059% R$ 1.3m
Carol Burt	Independent Director	5.8yrs	US$342.43k	0.0033% R$ 7.2m

8.1yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van I1QV34 wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.1 jaar).

IQVIA Holdings Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Iqvia Holdings Inc. Announces Transition of Kevin C. Knightly, President, Corporate Strategy and Enterprise Networks to Become A Senior Advisor to the Chief Executive Officer, Effective May 15, 2024

IQVIA Holdings Inc., Annual General Meeting, Apr 16, 2024

IQVIA Holdings Inc. Appoints Richard Staub III President of Research & Development Solutions

Iqvia Holdings Inc. Announces Resignation of Ronald A. Rittenmeyer as Member of the Board of Directors and Chairman of the Leadership Development and Compensation Committee

IQVIA Holdings Inc. Announces Executive Changes

IQVIA Appoints Christina Mack as Chief Scientific Officer of Real World Solutions, Effective from July 7, 2022

Recent updates

IQVIA Holdings Inc. Updates Earnings Guidance for the Full Year 2024

IQVIA Holdings Inc. to Report Q3, 2024 Results on Oct 31, 2024

IQVIA Holdings Inc. Updates Earnings Guidance for the Full Year 2024

IQVIA Holdings Inc. to Report Q2, 2024 Results on Jul 22, 2024

IQVIA Launches “One Home” Clinical Trial Technology Platform, Solves Challenges and Reduces Overload at Sitestes

Iqvia Holdings Inc. Announces Transition of Kevin C. Knightly, President, Corporate Strategy and Enterprise Networks to Become A Senior Advisor to the Chief Executive Officer, Effective May 15, 2024

IQVIA Holdings Inc. to Report Q1, 2024 Results on May 02, 2024

IQVIA Holdings Inc., Annual General Meeting, Apr 16, 2024

IQVIA Holdings Inc. Provides Earnings Guidance for the Full Year of 2024

IQVIA Holdings Inc. to Report Q4, 2023 Results on Feb 14, 2024

IQVIA Holdings Inc. Provides Financial Guidance for the Fourth Quarter and Full-Year of 2023

IQVIA Holdings Inc. to Report Q3, 2023 Results on Nov 01, 2023

IQVIA Holdings Inc. Appoints Richard Staub III President of Research & Development Solutions

IQVIA Holdings Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2023

IQVIA Holdings Inc. to Report Q2, 2023 Results on Aug 01, 2023

IQVIA Launches RIM Smart Labeling to Deliver Intelligence-Driven Approach for Global Label Management

IQVIA Holdings Inc. Provides Revenue Guidance for the Fiscal Year 2023

IQVIA Holdings Inc. to Report Fiscal Year 2022 Results on Feb 10, 2023

IQVIA Holdings Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Iqvia Holdings Inc. Announces Resignation of Ronald A. Rittenmeyer as Member of the Board of Directors and Chairman of the Leadership Development and Compensation Committee

IQVIA Announces its Decentralized Clinical Trial (DCT) Program Receives GDPR Compliance Validation from TRUSTArc

IQVIA Holdings Inc. Announces New Evidence That Decentralized Clinical Trials (DCT) Deliver Measurable Benefits for Patients, Sites and Sponsors

GSK plc and IQVIA launch Vaccine Track

IQVIA Holdings Inc. Announces Executive Changes

IQVIA Holdings Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2022

IQVIA Holdings Inc. to Report Q2, 2022 Results on Jul 21, 2022

IQVIA Appoints Christina Mack as Chief Scientific Officer of Real World Solutions, Effective from July 7, 2022

IQVIA Holdings Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2022

IQVIA Holdings Inc. to Report Q1, 2022 Results on Apr 27, 2022

IQVIA Holdings Inc. Selects to Support EMA’S DARWIN EU Coordination Centre Initiative

IQVIA Holdings Inc., Annual General Meeting, Apr 12, 2022

IQVIA Holdings Inc. Provides Financial Guidance for the First Quarter and Full Year 2022

IQVIA Holdings Inc. to Report Q4, 2021 Results on Feb 15, 2022

IQVIA Decentralized Trial Suite Launches Mobile Research Nursing and Phlebotomy Services Unit

IQVIA Launches New A.I.-Powered MI Contact Center for Life Sciences

IQVIA Launches the Clinical Data Analytics Suite to Enable Smarter, Faster Clinical Trials

IQVIA Announces That Mischaracterizes Nature of Recent Procedural E-Discovery Ruling in Veeva Systems Antitrust Case Against IQVIA

Iqvia Announces Connected Intelligence

IQVIA Holdings Inc. Provides Earnings Guidance for the Second Quarter of 2021

IQVIA Collaborates with Janssen Research & Development on Their Investigational Covid-19 Vaccine Trials

IQVIA Holdings Inc., Annual General Meeting, Apr 13, 2021

IQVIA Holdings Inc. Raises Earnings Guidance for the Full Year of 2021

IQVIA Holdings Inc. to Report Q4, 2020 Results on Feb 10, 2021

Laboratoires Théa Selects Iqvia Oce and Onekey to Accelerate Its Global Digital Transformation

IQVIA and Servier Collaborate to Reinvent Clinical Development

IQVIA’s Orchestrated Customer Engagement Platform Selected by Zentiva to Accelerate Digital Capabilities

IQVIA Joins U.S. Food and Drug Administration to Advance COVID-19 Understanding at Community Level through COVID Active Research Experience (CARE) Project

IQVIA Holdings Inc. to Report Q3, 2020 Results on Oct 20, 2020

IQVIA Holdings Inc. to Report Q2, 2020 Results on Jul 22, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd